These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30510243)

  • 1. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
    Zhou D; Chen YW; Zhao ZH; Yang RX; Xin FZ; Liu XL; Pan Q; Zhou H; Fan JG
    Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30510243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
    Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
    Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice.
    Yang T; Yang H; Heng C; Wang H; Chen S; Hu Y; Jiang Z; Yu Q; Wang Z; Qian S; Wang J; Wang T; Du L; Lu Q; Yin X
    Food Funct; 2020 Dec; 11(12):10675-10689. PubMed ID: 33216087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene.
    Zhao ZH; Wang ZX; Zhou D; Han Y; Ma F; Hu Z; Xin FZ; Liu XL; Ren TY; Zhang F; Xue Y; Cui A; Liu Z; Bai J; Liu Y; Cai G; Su W; Dai X; Shen F; Pan Q; Li Y; Fan JG
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):857-871. PubMed ID: 33989817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.
    Valdecantos MP; Ruiz L; Pardo V; Castro-Sanchez L; García-Monzón C; Lanzón B; Rupérez J; Barbas C; Naylor J; Trevaskis JL; Grimsby J; Rondinone CM; Valverde ÁM
    Sci Rep; 2018 Nov; 8(1):16461. PubMed ID: 30405191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
    Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
    World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
    Zhang N; Qu Y; Qin B
    Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1125-1136. PubMed ID: 33721354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
    Liu Y; Wei R; Hong TP
    World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
    Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
    J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
    Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
    Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal perfusion of unacylated ghrelin alleviated metabolically associated fatty liver disease in rats via a central glucagon-like peptide-1 pathway.
    Lv P; Li H; Li X; Wang X; Yu J; Gong Y
    Am J Physiol Gastrointest Liver Physiol; 2024 Jun; 326(6):G643-G658. PubMed ID: 38564323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
    Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis.
    Yokomori H; Ando W
    BMJ Open Gastroenterol; 2020 May; 7(1):. PubMed ID: 32414752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1.
    Liu J; Wang F; Liu S; Du J; Hu X; Xiong J; Fang R; Chen W; Sun J
    J Neurol Sci; 2017 Oct; 381():176-181. PubMed ID: 28991675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
    Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
    PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.